Observational studyBMC primary care2026
Antibiotic treatment for respiratory tract infections for migrants in Norway during the COVID-19 pandemic: a population-wide registry study.
Observational study in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory tract infections (RTIs) are a common reason for seeking primary health care services and are one of the main reasons for antibiotic prescriptions in primary care. The COVID-19 pandemic impacted migrants differently from the majority population in Norway.
objectivesTo investigate the likelihood of antibiotic treatment for RTIs in primary care before and during the COVID-19 pandemic, and types of antibiotics used, for selected migrant populations and Norwegian-born, in Norway.
methodsObservational study on adults from Norway, Poland, Somalia, Sri Lanka, and Syria, using primary health service and demographic data from individually linked registries from Norway 2018–2021. We compared the pandemic to the pre-pandemic period using modified Poisson regression to estimate the relative risk of antibiotic treatment for RTIs during the COVID-19 pandemic.
resultsThe relative risk, with confidence intervals in parentheses, of antibiotic treatment for RTIs during the pandemic, by country of birth, was 0.51 (0.51–0.52) for Norway, 0.45 (0.43–0.48) for Poland, 0.41 (0.38–0.45) for Somalia, 0.45 (0.40–0.50) for Sri Lanka, and 0.54 (0.49–0.58) for Syria. Phenoxymethylpenicillin was the most common antibiotic for RTIs, accounting for 48.5–65.3% of treatments, depending on country of birth.
conclusionAll groups, irrespective of country of birth, had approximately half the antibiotic treatment rate for RTIs during the pandemic, compared to the pre-pandemic period. The most used antibiotic type was phenoxymethylpenicillin, and the distribution of antibiotic types was relatively stable over time, for all countries of birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.